4503.T
Strong BuyUnloved QualityAI neutralAstellas Pharma Inc. · Healthcare · Japan · $26.9B
JPY 2,243.5 +0.4% · close 6 Oct · scored 7 Oct
Unloved Quality: Strong and cheap; the market has not turned yet.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Astellas Pharma is a major Japanese biopharmaceutical company with key global commercial franchises in oncology and urology. While long-term cash flow generation remains intact, recent downward consensus revisions to near-term earnings reflect near-term loss-of-exclusivity challenges for legacy therapies and launch costs for newer pipeline assets.
ABOUT ASTELLAS PHARMA INC.
Read
Astellas Pharma Inc. is a major Japanese pharmaceutical company dedicated to the research, development, manufacturing, and marketing of innovative prescription drugs in therapeutic areas such as oncology, urology, and immunology. The company's competitive moat is built on a robust R&D pipeline focused on breakthrough therapies and a global commercial footprint. Astellas is a leading global pharmaceutical firm, committed to scientific innovation to address critical unmet medical needs.
FINANCIAL SUMMARY (JPY)
| Year | 2022 | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 1.5T | 1.6T | 1.9T | 2.1T | 12.1% | 2.3T | 2.3T | 2.2T | 1.2% |
| EPS (JPY) | 67.08 | 54.24 | 9.51 | 28.35 | 162.77 | 24.8% | 162.81 | 169.04 | 160.65 | -0.7% |
| Shares | — | 1.8B | 1.8B | 1.8B | 1.8B | -0.3% | 1.8B | — | — | — |
| Debt | — | 125.0B | 920.0B | 831.4B | 566.0B | 65.4% | 591.7B | — | — | — |
| Equity | — | 1.5T | 1.6T | 1.5T | 1.8T | 6.6% | — | — | — | — |
| Op CF | — | 327.8B | 172.5B | 194.5B | 560.2B | 19.6% | 593.7B | — | — | — |
| Inv CF | — | -84.5B | -845.8B | -89.4B | -66.7B | — | — | — | — | — |
| Fin CF | — | -195.6B | 614.1B | -261.4B | -404.8B | — | — | — | — | — |
Calmer than 73% of stocks we rank over the past year (30% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 4503.T are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 4503.T | Astellas Pharma Inc.(you) | $26.9B | 97 | Strong Buy |
| 4578.T | Otsuka Holdings Co., Ltd. | $36.6B | 91 | Strong Buy |
| 4528.T | Ono Pharmaceutical Co., Ltd. | $7.2B | 95 | Strong Buy |
| 4536.T | Santen Pharmaceutical Co., Ltd. | $3.5B | 95 | Strong Buy |
| 4568.T | Daiichi Sankyo Company, Limited | $33.3B | 52 | Hold |
| 4519.T | Chugai Pharmaceutical Co., Ltd. | $69.4B | 66 | Buy |
| 7741N.MX | HOYA Corporation | $47.0B | 96 | Strong Buy |
| 4543.T | Terumo Corporation | $21.2B | 81 | Strong Buy |
| 7733.T | Olympus Corporation | $13.5B | 82 | Strong Buy |
| 6869.T | Sysmex Corporation | $7.1B | 91 | Strong Buy |
Peer medians: ROE 8.3% · P/E 15.7x · Gross margin 47.0%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.